11:24 AM
 | 
Jan 12, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Akcea starts Phase IIb of AKCEA-APOCIII-LRx in hypertriglyceridemia

Akcea Therapeutics Inc. (NASDAQ:AKCA) began a double-blind, placebo-controlled Phase IIb trial to evaluate four doses of AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx) in 100 patients with hypertriglyceridemia and established cardiovascular disease (CVD). AKCEA-APOCIII-LRx is a ligand conjugated antisense version of an oligonucleotide targeting apolipoprotein C-III (APOCIII; APOC3).

The trial's primary...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >